Compare MAGN & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MAGN | DSGN |
|---|---|---|
| Founded | 1864 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Paper | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 521.2M | 504.7M |
| IPO Year | N/A | 2021 |
| Metric | MAGN | DSGN |
|---|---|---|
| Price | $14.54 | $9.72 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $16.00 | $13.50 |
| AVG Volume (30 Days) | ★ 930.3K | 504.3K |
| Earning Date | 02-05-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,204,000,000.00 | N/A |
| Revenue This Year | $5.74 | N/A |
| Revenue Next Year | $2.51 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 46.50 | N/A |
| 52 Week Low | $7.82 | $2.60 |
| 52 Week High | $23.19 | $10.31 |
| Indicator | MAGN | DSGN |
|---|---|---|
| Relative Strength Index (RSI) | 64.64 | 58.56 |
| Support Level | $14.56 | $8.43 |
| Resistance Level | $15.20 | $10.11 |
| Average True Range (ATR) | 0.48 | 0.68 |
| MACD | -0.13 | -0.06 |
| Stochastic Oscillator | 56.29 | 66.07 |
Magnera Corp is a supplier of a diverse portfolio of specialty materials comprised of organic and synthetic raw ingredients. The company markets its own products predominantly into stable, consumer-oriented end markets, including wipes, healthcare, adult incontinence, apparel, baby, feminine care, air filtration, and food and beverage, for disposable and durable applications. It also provides technical solutions in infrastructure markets. The company's operations are organized into two operating and reportable segments: Americas and Rest of World. It derives the majority of its revenue from the Americas, which manufactures products and components of personal care, including medical garments, wipes, dryer sheets, filtration, baby diapers and adult incontinence.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.